Drug intelligence / Profile preview

Yiqi Tongqiao Pills

Development stage: Unknown
Lead developer: Yangtze River Pharmaceutical Group
Administration: Oral

Overview

Yiqi Tongqiao Pills is a Traditional Chinese Medicine (TCM) patent medicine developed as a hospital-made preparation by Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University). It is primarily indicated for the treatment of allergic rhinitis. The formulation is based on TCM principles intended to "tonify Qi" (Yiqi) and "open the orifices" (Tongqiao), specifically targeting the nasal passages. It is often evaluated in real-world clinical settings in China, either as a standalone therapy or in combination with Western medicines like antihistamines or nasal corticosteroids, to assess its effectiveness in reducing symptoms such as sneezing, nasal itching, and congestion through immunomodulatory and anti-inflammatory effects.

Other names: Yiqi Tongqiao Wan益气通窍丸

Beyond the preview

Go deeper on Yiqi Tongqiao Pills.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yiqi Tongqiao Pills.

Explore the full profile